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Background
Associated treatment with pegylated interferon plus spe-
cific antiviral compounds significantly improved the
prognosis of chronic hepatitis C and hepatitis B even
when an underlying HIV infection is of concern,
although antiviral drugs (especially interferon and its
derivatives), tend to be myelotoxic and also some rescue
treatments, like human recombinant granulocyte col-
ony-stimulating factors (G-CSF, filgrastim or lenogras-
tim) (which are extensively administered in order to
correct neutropenia induced by antiviral therapy), may
also be involved in prompting or exacerbating cutaneous
psoriasis and its systemic complications.
Methods
A representative case report of a HCV-monoinfected
woman with no personal and familial history of psoriasis,
who suffered from a chronic, progressive, evolutive hepati-
tis C, underwent long-term treatment with combined
pegylated interferon plus ribavirin, and resorted to multiple
cycles of G-CSF (filgrastim), in order to recover a severe,
recurring granuloytopenia caused by antiviral therapy itself,
and to maintain an effective dosage of both anti-HCV
antivirals.
Results
Five months after treatment initiation, she suddenly devel-
oped an extensive and severe cutaneous psoriasis, which did
not benefit from all attempted local therapies, and improved
only after specific cyclosporin treatment. Anti-HCV therapy
was first interrupted, and then continued with a lowered
dosages of peg-interferon and ribavirin, so that a sustained
anto-HCV therapeutic response was not obtained.
Discussion
From a pathogenetic point of view, in our case it remains
extremely difficult to distinguish the role of pergylated
interferon from that of the accompanying ribavirin, from
that of the frequently administered granulocyte growth
factor (filgrastim in our case), since all mentioned drugs
were administered concurrently during many months, and
according to the existing literature evidences, all of them
have a potential to induce/exacerbate psoriasis as a poten-
tial untoward effect in subjects suffering from chronic
hepatitis. Cyclosporin treatment obtained a stable remis-
sion of this last severe cutaneous complication, but the
efforts to contain the progression the underlying evolutive
hepatitis C were blunted by the difficult-to-treat genotype
1 HCV infection, and the frequent need to lower drug
dosages and/or to interrupt antiviral therapy, because of
initial myelotoxicity and subsequent cutaneous complica-
tions, probably driven by anti-HCV therapy itself.
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